Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Recruiting

Phase 1

Phase 2

Sacituzumab Tirumotecan & PembrolizumabSubstudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06469944

Conditions

Gastroesophageal Junction

Gastroesophageal Adenocarcinoma

Esophageal Neoplasms

Esophageal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Sacituzumab Tirumotecan (sac-TMT)

Capecitabine

Leucovorin

Levoleucovorin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-05-06.